Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/01/23
End: 08/31/25
Due: 08/31/26
Phase: N/A
Priority: Normal
Start: 07/05/22
End: 05/18/23
Due: 05/18/24
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS | NCT05938036 | Aqualung Therapeutics Corp. | user2@example.com | None | 2023-12-01 | 2025-08-31 | 2026-08-31 | - | - | 2025-07-14 |
| First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALT-100 | NCT05426746 | Aqualung Therapeutics Corp. | user2@example.com | None | 2022-07-05 | 2023-05-18 | 2024-05-18 | - | - | 2025-07-14 |